<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Physiology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/46FBC227-56AA-437C-AF3F-75CEB9BBD7A8"><gtr:id>46FBC227-56AA-437C-AF3F-75CEB9BBD7A8</gtr:id><gtr:firstName>Hannah</gtr:firstName><gtr:otherNames>Frances</gtr:otherNames><gtr:surname>Clarke</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100307"><gtr:id>98743012-698A-4300-A358-0BB53C81994E</gtr:id><gtr:title>Serotoninergic modulation of hippocampal-prefrontal circuitry and the control of negative emotional regulation</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100307</gtr:grantReference><gtr:abstractText>Imagine walking down a dark street at night. Hearing unexpected footsteps behind you, you feel fear, your heart races, and you get ready to run - aspects of our complex emotional response. Abnormal emotional regulation causes major problems, and is seen in anxiety, depression, and schizophrenia. These disorders are treated with drugs influencing serotonin, but serotonin acts on many different brain regions and receptors. In disorders such as depression, specific brain regions are abnormal, including the amygdala (well known to influence emotional responses) but also the hippocampus and prefrontal cortex. How these structures contribute to normal emotional regulation, go wrong, and are influenced by serotonin is poorly understood. I will use tasks in monkeys that measure emotional biasing of perception (the glass half empty effect seen in depression), and how heart rate, blood pressure and behaviour alter in response to stimuli that unreliably predict emotional events. I will investigate the contribution of the hippocampus and prefrontal cortex to physiological and behavioural aspects of emotion by inactivating them, and altering their serotonin signalling using specific drugs. This will improve our understanding of how these regions control emotions and of the brain basis of disorders blighting the lives of millions.</gtr:abstractText><gtr:technicalSummary>The ability to regulate one?s emotions appropriately in response to salient stimuli is crucial in our interaction with the environment. Emotional dysregulation features commonly in disorders such as depression and anxiety. It may result from cognition being abnormally biased by emotive stimuli, and from failure to integrate the behavioural and physiological aspects of emotional responses. However, the neural bases of emotional response integration and cognitive biases are poorly understood. Therapies for affective disorders primarily target serotonergic systems, while genetic polymorphisms affecting serotonin (5-HT) and alterations in 5-HT receptor levels are well documented within the affective disorders. Abnormal medial prefrontal cortex (mPFC) responses to affective feedback are seen in depressed patients and healthy humans following serotonergic manipulations, while hippocampal 5-HT is involved in the processing of some aversive cues. However, the roles of the hippocampus, mPFC, and their serotonergic innervation in the influence of emotional stimuli on cognitive processing and in emotional response integration are unknown. To investigate the negative interpretational bias seen in emotional responses to ambiguous stimuli in affective disorders (the ?glass half empty? syndrome), a newly adapted behavioural paradigm will be applied to the marmoset, allowing discriminative performance and affective bias to be measured. Mood induction techniques will be used to produce an affective bias, and the effects of intra-hippocampal fluoxetine, intra-hippocampal 5-HT1A receptor antagonism, and intra-mPFC 5-HT2a receptor agonism and antagonism (in mPFC subregions of a priori interest) evaluated. This will identify the causal role of hippocampal and mPFC 5-HT in negative bias symptomatology. To investigate how these structures regulate the behavioural and physiological aspects of an emotional response, a remote telemetric procedure allowing simultaneous measurement of cascular and behavioural responses to ambiguous emotive stimuli will be employed. Excitotoxic hippocampal and mPFC subregion lesions and inactivations will test hypotheses concerning the role of these structures in the acquisition, extinction and expression of autonomic and behavioural responses to ambiguously predictive cues, while focal administration of 5-HT1A/5HT2A agonists and antagonists will establish the serotonergic contribution to these behaviours. Together, these studies will identify how the hippocampus and mPFC contribute to abnormal emotive cognitive bias and dysregulation of the physiological and behavioural integration of an emotional response, and serotonin?s contribution to such pathological processes. This information is critical to our understanding of the aetiology of specific symptom clusters within affective and other psychiatric disorders, and may eventually lead to developments in pharmacotherapy better targeted to dysfunctional regions of interest.</gtr:technicalSummary><gtr:fund><gtr:end>2017-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>682453</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>invited speaker - Bristol University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C7DE48E9-0C53-42F4-A32D-ACB01FC9109B</gtr:id><gtr:impact>promoting marmoset research and sharing data for discussion</gtr:impact><gtr:outcomeId>58c02bfa456281.99539319</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>invited speaker - Oxford University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6B2D1716-1588-4A38-822B-8360B88D0A05</gtr:id><gtr:impact>promoting marmoset research and data discussion</gtr:impact><gtr:outcomeId>58c02c64d8a9f8.74954616</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Organiser of minisymposium at the Society of Neuroscience 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B98C90F7-296B-4FD6-8D12-07B093920D8A</gtr:id><gtr:impact>I organised a highly competitive minisymposium application at the Society for Neuroscience International meeting in Chicago in 2015. The application was successful so I chaired and spoke at the symposium.</gtr:impact><gtr:outcomeId>56dd7d50611bc0.45057925</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>22100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Equipment Funding Competition</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>944D72F4-4C4B-44D2-BE76-2C0A0EAE7E48</gtr:id><gtr:outcomeId>5459fbb42dd9a0.97875463</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Apointment to the Animals in Science (Home Office) Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95A3F25F-90B1-4B5D-81E4-BC2E8E5FEBFD</gtr:id><gtr:outcomeId>58c02d17c0ca36.02379438</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>https://www.gov.uk/government/organisations/animals-in-science-committee</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The dexamethasone suppression test was originally designed to diagnose and differentiate among the various types of hypercortisol states but more recently has shown considerable utility in studies of depression. I have now developed a marmoset analogue of this test.</gtr:description><gtr:id>1551F8C3-DBF6-4138-A4ED-8629A25A7F2D</gtr:id><gtr:impact>N/A yet, but will be of use in assessing the impact of brain manipulations on potentially depressive states that may result from brain manipulations.</gtr:impact><gtr:outcomeId>AzpGJsZdvBt</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Marmoset dexamethasone suppression test</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I now have an in vitro assay working in the marmoset to quantify BDNF levels from cytosolic protein samples from different brain regions.</gtr:description><gtr:id>A5C47A63-8156-44C0-ADA9-6B6840BCE951</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>G99J1yFwWBd</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>marmoset BDNF assay</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I have developed techniques for the peripheral measurement of cortisol levels in awake marmosets from both hair and saliva. These assays allow assessment of HPA axis reactivity in both chronic (hair) and acute (saliva) states without requiring sedation of the marmoset for blood sampling, and provide a physiological measure of emotional reactivity.</gtr:description><gtr:id>C706132D-50B7-4882-B858-90C9405A3F2F</gtr:id><gtr:impact>N/A yet, but I am currently screening animals for emotional reactivity prior to inclusion in behavioural studies. Consequently it will be possible to assess how both long term (excitotoxic or neurochemical brain lesion) and acute (drug infusion to specific brain regions via cannulation) brain manipulations modulate emotional/HPA reactivity</gtr:impact><gtr:outcomeId>A4YAsseM2Kk</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Peripheral cortisol assay in marmosets</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Inhalation of 7.5% CO2 is a well-validated mechanism of inducing mild anxiety in humans. I have now developed an equivalent version for marmosets.</gtr:description><gtr:id>3B656E0A-D99B-42EB-A7AC-F76F96E3F793</gtr:id><gtr:impact>I know have a clear example of what an anxiety response looks like. I can use this to judge other potentially anxiogenic or anxiolytic manipulations against.</gtr:impact><gtr:outcomeId>5459f8afcc9e10.31737408</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Inhalation of 7.5% CO2</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E1728E49-392D-453A-B8F2-783E42BBFD04</gtr:id><gtr:title>Neuroimaging in primates carrying variants of a novel serotonin transporter polymorphism reveals differences in serotonin 2A receptor binding in the insula and morphological volume changes in the anterior hippocampus</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a283a99bed46b208371bf2280e1ba71f"><gtr:id>a283a99bed46b208371bf2280e1ba71f</gtr:id><gtr:otherNames>SANTANGELO, Andrea</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>AoHZnN4r9aR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CAB754C-2DE4-42BB-92A7-838417D1E032</gtr:id><gtr:title>Normalising high trait anxiety in monkeys; the role of hippocampal-medial prefrontal circuitry.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8386ffc94c4c5b0acb0eb44d7e84bc63"><gtr:id>8386ffc94c4c5b0acb0eb44d7e84bc63</gtr:id><gtr:otherNames>Zeredo J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5459f43d5d24b3.70319678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4FAEBD5-8D88-4559-A84E-B93A87FB452C</gtr:id><gtr:title>Do sub-regions of the marmoset medial PFC differentially regulate a negative emotional response?</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1296c8ddb09b7f5eab9a293223e3bab7"><gtr:id>1296c8ddb09b7f5eab9a293223e3bab7</gtr:id><gtr:otherNames>Wallis CW</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5459f5a1cbd9a6.91043772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>587BD08C-D334-4BE4-A706-87A75E43F38C</gtr:id><gtr:title>Fronto-subcortical circuits and avoidance behaviour: differential contributions of the orbitofrontal and ventrolateral PFC.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d3ae7b0f559bda4fc815311855c0c45"><gtr:id>5d3ae7b0f559bda4fc815311855c0c45</gtr:id><gtr:otherNames>Clarke HF</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5459f3d5cb7ff5.56516620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E387C576-A95D-475A-B939-C12C3C23F6C4</gtr:id><gtr:title>Regional inactivations of primate ventral prefrontal cortex reveal two distinct mechanisms underlying negative bias in decision making.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d3ae7b0f559bda4fc815311855c0c45"><gtr:id>5d3ae7b0f559bda4fc815311855c0c45</gtr:id><gtr:otherNames>Clarke HF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d43d177f77e0.59292148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF1774F0-FE1D-4EF0-9E93-229F6ABDD0AB</gtr:id><gtr:title>Opposing roles of primate areas 25 and 32 and their putative rodent homologs in the regulation of negative emotion.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a6c5c62c05a2a45253f287ceb4bb01"><gtr:id>b9a6c5c62c05a2a45253f287ceb4bb01</gtr:id><gtr:otherNames>Wallis CU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58c02ab3687755.65801765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>534A5A7B-872A-4DC2-A7CA-E6583C52A1AE</gtr:id><gtr:title>Fronto-subcortical circuits and avoidance behaviour: differential contributions of the orbitofrontal and ventrolateral PFC</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd3e7ecf595136ea29609891eb8f62d3"><gtr:id>cd3e7ecf595136ea29609891eb8f62d3</gtr:id><gtr:otherNames>Clarke H</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5459f9409df813.56589105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B948356-5BEF-44BE-B2B8-9F7803805D5E</gtr:id><gtr:title>Anticipatory Anhedonia Induced by Overactivation of Subgenual Cingulate is Reversed by Ketamine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5ad348672b46341a8c5b1e53f8d66a4"><gtr:id>a5ad348672b46341a8c5b1e53f8d66a4</gtr:id><gtr:otherNames>Alexander L.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c029604749c2.73453536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4B419B6-1A90-4801-A1A3-7C72C851B9DA</gtr:id><gtr:title>Do sub-regions of the marmoset medial PFC differentially regulate a negative emotional response?</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1296c8ddb09b7f5eab9a293223e3bab7"><gtr:id>1296c8ddb09b7f5eab9a293223e3bab7</gtr:id><gtr:otherNames>Wallis CW</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5459f7de22c6b1.41182585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5048298D-869A-4AEA-9C34-47DF92E0AF7B</gtr:id><gtr:title>A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey.</gtr:title><gtr:parentPublicationTitle>Developmental neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6df1bdd6a742f853d8d490aa2271ddeb"><gtr:id>6df1bdd6a742f853d8d490aa2271ddeb</gtr:id><gtr:otherNames>Oikonomidis L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-8451</gtr:issn><gtr:outcomeId>58c02a3d37e2e6.00422549</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100307</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>